Ketamine for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 31 Oct 2024: Trial registered, NCT06668571
  2. 10 Feb 2025: Trial started, NCT06668571

The trials

NCT05137938: Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)

State
Completed
Phase
No phase
People
25 taking part
Started
25 Oct 2021
Primary completion
24 Jul 2023
Arms
Intranasal Ketamine (IN)
Results
None posted
  1. 25 Oct 2021: Trial started
  2. 30 Nov 2021: Trial registered
  3. 24 Jul 2023: Trial completed

NCT06668571: Intravenous Ketamine for Treatment-Resistant Depression

State
Under way
Phase
Phase 2
People
30 planned
Started
10 Feb 2025
Primary completion
31 Dec 2027
Arms
Ketamine Group
Results
None posted
  1. 31 Oct 2024: Trial registered
  2. 10 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 0.2 mg/kg ketamine, 1st perfusion of ketamine, 2nd perfusion of ketamine, Anaket v, Calypsol, CLORKETAM 1000, IMALGENE 1000, Intranasal Ketamine (IN), Intranasal ketamine, Ketafol component ketamine, KETASOL 100, Ketamine Infusion, Narketan, Tekam, Ursotamin, Vetaket.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.